ArticleTranslational oncology2013
Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.
Article in Translational oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- Identification of a Preliminary Plasma Metabolome-based Biomarker for Circadian Phase in Humans.Journal of biological rhythms · 2021Trial
- Trial
- Metabolic Fingerprinting of Urine Reveals Metabolite Changes in Women With Breast Cancer.Cancer medicine · 2026Article
- Cross-population metabolome-wide Mendelian randomization study of prostate cancer risk.Research square · 2026Article
- Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study.Scientific reports · 2026Article
- Elucidating the causal effects of plasma metabolites on breast cancer from multiple perspectives.International journal of surgery (London, England) · 2026Article
- Amino acid metabolism in breast cancer: pathogenic drivers and therapeutic opportunities.Protein & cell · 2025Review
- Metabolomics Biomarker Discovery to Optimize Hepatocellular Carcinoma Diagnosis: Methodology Integrating AutoML and Explainable Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2024Article
- A Multiomics, Molecular Atlas of Breast Cancer Survivors.Metabolites · 2024Article
- Screening of postoperative adjuvant chemotherapy-related serum metabolic markers in breast cancer patients based onTranslational cancer research · 2024Article
- Differences in metabolomic profiles between Black and White women in the U.S.: Analyses from two prospective cohorts.European journal of epidemiology · 2024Article
- Article
- The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review.Current issues in molecular biology · 2023Review
- Identification of metabolic pathways contributing to ERScientific reports · 2023Article
- Article
- Article
- Metabolomic Analysis of Plasma from Breast Cancer Patients Using Ultra-High-Performance Liquid Chromatography Coupled with Mass Spectrometry: An Untargeted Study.Metabolites · 2022Article
- Impact of the PdInternational journal of molecular sciences · 2021Article
- Free Amino Acid Alterations in Patients with Gynecological and Breast Cancer: A Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Prediagnostic circulating metabolites in female breast cancer cases with low and high mammographic breast density.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundA few studies in the last several years have shown that metabolomics, the study of metabolites and small intermediate molecules, may help better understand the breast carcinogenesis. However, breast cancer is a heterogeneous disease with different subtypes. Additionally, there is a significant racial difference in terms of breast cancer incidence and mortality. Few, if any, metabolomics studies in breast cancer have considered race and tumor subtypes in the study design.
methodsWe performed a global metabolomic profiling using mass spectrometry and samples from 60 breast cancer cases and 60 matched controls.
resultsA total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10). Most of those differentiated metabolites belong to amino acids, fatty acids, and lysolipids. In the pathway-based analysis, we found that plasma levels of many amino acids were statistically significantly lower in patients with breast cancer, especially those with triple-negative breast cancer, than healthy controls. However, plasma levels of many FAs related to β-oxidation were statistically significantly higher in patients with breast cancer than healthy controls, suggesting the possibility of altered FA β-oxidation in patients with breast cancer.
conclusionsBecause of small sample size, the clinical usage of the metabolites from this study is unclear. Further validation of those significant metabolites is warranted, especially with the consideration of racial difference.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.